Humanwell Pharmaceuticals’ RFUS-949 tablet clinical trial approved
May 31, 2025
Source: drugdu
80
On May 29, Humanwell Pharmaceutical issued an announcement that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for RFUS-949 tablets approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of this product for acute and chronic pain.
RFUS-949 is a new molecular entity developed by Yichang Renfu, and is registered as a Class 1 chemical drug. RFUS-949 tablets are intended to be used clinically for the treatment of acute and chronic pain. Currently, no similar products have been approved for marketing in China. So far, Yichang Renfu's cumulative R&D investment in this project is approximately RMB 15 million.
In the first quarter of 2025, Renmin Pharmaceutical achieved revenue of 6.137 billion yuan and net profit attributable to shareholders of the parent company of 540 million yuan.
https://finance.eastmoney.com/a/202505293417929589.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Is Drug Working? Still Needed? July 14, 2025
- FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC July 14, 2025
- KYS2301 gel approved for clinical use in atopic dermatitis July 14, 2025
- Innovent Biologics’ Enzeshu was approved for marketing, becoming China’s first targeted drug for all patients with platinum-resistant ovarian cancer July 14, 2025
- CStone Pharmaceuticals and Istituto Gentili Enter into European Commercialization Collaboration July 14, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
